CRNX20260717C26
CRNX Jul 17 2026 26.00 Call (CRNX260717C00026000)
option OPRA

neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.